Association between rs735482 polymorphism and risk of cancer

A meta-analysis of 10 case–control studies

Shilin Xue, BDa, Wenya Shen, MDb, Jianning Cai, MDc, Jinhai Jia, MDd, Dan Zhao, BDe, Shan Zhang, BDf, Xiujun Zhao, PhDb, Ning Ma, e, Wenjuan Wang, e, Bingshuang Wang, MED, Xiaolin Zhang, PhDg, Xuehui Liu, PhDh,*

Abstract
Several studies have inspected the relationship between rs735482 polymorphism and the risk of some human cancers, but the findings remain controversial. We designed this meta-analysis to validate the association between rs735482 polymorphism and cancer risk. All articles were published before September 1, 2018 and searched in Pubmed, Embase, Web of Science, China National Knowledge Infrastructure, WangFang, and Chinese BioMedical databases, STATA 12.0 software was used for statistical analysis, which provides reasonable data and technical support for this article. A total of 10 studies were included in the meta-analysis, including 2652 cancer cases and 3536 rs735482 polymorphic controls. Data were directly extracted from these studies and odds ratios with 95% confidence intervals were computed to estimate the strength of the association. By pooling all eligible studies, the rs735482 polymorphism showed no significant association with susceptibility of several cancers in all the five genetic models (the allelic model: OR = 1.019, 95% CI: 0.916–1.134, \( P = .731 \)). In addition, another adjusted OR data showed a significant increased risk between the rs735482 and susceptibility of several cancers (the codominant model BB vs AA: OR = 1.353, 95% CI: 1.033–1.774, \( P = .028 \)) and the stratification analysis by ethnicity indicated the rs735482 is associated with an increased risk of cancer in Chinese group (BB vs AA, OR = 1.391, 95% CI = 1.054–1.837, \( P = .020 \); BB + AB vs AA OR = 1.253, 95% CI = 1.011–1.551, \( P = .039 \)). However, the ERCC1 rs735482 is associated with a decreased risk of cancer in Italian group (AB vs AA, OR = 0.600, 95% CI = 0.402–0.859, \( P = .012 \); AB + BB vs AA, OR = 0.620, 95% CI = 0.424–0.908, \( P = .014 \)). The results of this meta-analysis do not support the association between rs735482 polymorphism and cancer risk. But stratified analysis showed that rs735482 significantly increased the risk of cancer in Chinese while decreased the risk of cancer in Italian. Because of the limited number of samples, larger and well-designed researches are needed to estimate this association in detail.

Abbreviations: CNKI = China National Knowledge Infrastructure, ERCC1 = excision repair cross complementation group 1, HWE = Hardy–Weinberg equilibrium, NER = nucleotide excision repair, OR = odds ratio.

Keywords: cancer, meta-analysis, polymorphism, rs735482, susceptibility

1. Introduction
Cancer is one of the major causes of morbidity and mortality and poses a major threat to public health worldwide. The occurrence of different cancer varies widely among different racial and ethnic groups which may be partly due to the lifestyle and genetic background. The complex interactions of multitudinous gene loci and various environmental factors play an important role in the development of cancer.

SX, WS, and JC contributed equally to this work.

Sources of support: Youth fund projects of education department of Hebei province (QN2015010); Natural Science Foundation of Hebei Province (H2021206401).

The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

*aSchool of Basic Medical Sciences Peking University, Peking University Health Science Center, Beijing, China; *Department of Occupational and Environmental Health, School of Public Health, Hebei Medical University, Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, Hebei, China; *Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University, Hebei Province Key Laboratory of Environment and Human Health, Shijiazhuang, Hebei, China.

*Correspondence: Xuehui Liu, Department of Occupational and Environmental Health, School of Public Health, Hebei Medical University, Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, China (e-mail: lxh19762006@163.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Xue S, Shen W, Cai J, Jia J, Zhao D, Zhang S, Zhao X, Ma N, Wang W, Wang B, Zhang X, Liu X. Association between rs735482 polymorphism and risk of cancer: A meta-analysis of 10 case–control studies. Medicine 2022;101:30(e29318).

Received: 30 March 2020 / Received in final form: 31 March 2022 / Accepted: 31 March 2022
http://dx.doi.org/10.1097/MD.0000000000029318
rs735482 maps in the 3-UTR of excision repair complementation group 1 (ERCC1) gene and it also maps in the coding sequence of CD3EAP, a gene that overlaps with ERCC1 but is transcribed in the opposite direction. But their functions are different. The CD3EAP is located between ERCC2 and ERCC1 in the chromosomal region 19q13.3. The CD3EAP products can mediate the activation signal generated by interleukin-2 in T cells.[9] In humans, the CD3EAP has the same part of the coding sequence as ERCC1. This indicated that these genes are linked to some important biological functions.[4] Large population studies have shown that CD3EAP rs735482 polymorphism has a potential impact on the risk of lung cancer and ItaKs represent significant association with susceptibility of lung cancer.[5,6] CD3EAP rs735482 on Chr19q13.3 were strongly associated with lung cancer risk both in Asian Chinese and in Caucasian Danes.[7]

The CD3EAP rs735482 polymorphism results in changes in amino acid 259 (AAA to ACA: K [lysine] to T [threonine]). The missense mutation might affect CD3EAP protein function. ERCC1 located on chromosome 19q13.3.[8–10] is an important factor involved in the DNA damage incision, and its products play an important role in nucleotide excision repair (NER). ERCC1 protein, as a highly conserved enzyme, is the main component in the NER process and an essential part of the NER cutting procedure. ERCC1 acts as an endonuclease that incises 5’-3’ damaged DNA strand, allowing the removal of the damaged strand, polymerization, and relegation.

Epidemiological studies have shown that genetic mutations in ERCC2 and ERCC1 may be associated with various cancer risks.[11–13] Two independent genes, ERCC1 and ERCC2, encode the same mature ERCC1 sequence.[14] Currently, many studies detected the association between ERCC1 rs735482 polymorphism and risk of various cancers, including breast cancer, cervical cancer, esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, neuroblastoma, non-small cell lung cancer and other cancers, but the results are still controversial.[15–23] Therefore, we conducted a meta-analysis to find out the effect of rs735482 polymorphism on cancer risk.

2. Materials and Methods

2.1. Literature search

Comprehensive literature searches were conducted for all articles published up to September 30, 2019 in Pubmed, Embase, Web of Science, China National Knowledge Infrastructure, WangFang Date, and Chinese BioMedical databases. These articles described an association between rs735482 polymorphism and cancer risk. The search keywords were “cancer, polymorphism, rs735482.” The process of identifying qualified studies is shown in Figure 1. Criteria for selection of eligible studies included:

1. the original studies;
2. studies on the association between rs735482 polymorphism (s) and cancer risk;
3. studies that reported odds ratio (OR) with 95% confidence interval (CI) values or sufficient data to calculate OR and 95% CI.

The exclusion criteria were:

1. case-only studies, family-based studies, conference summaries, and review article;
2. overlapping data;
3. insufficient genotype information provided. Because this study is a meta-analysis, ethical approval is not necessary.

2.2. Data extraction

Two authors searched the literature independently, extracted relevant data, and any disagreement was decided by the third author through discussion. The following data were extracted for each study, including the first author’s name, year of publication, country, ethnicity of participants, number of genotypes in the case-control groups, results of the Hardy–Weinberg equilibrium (HWE) test (Table 1). Another adjusted OR data were extracted for each study including the first author’s name, year of publication, country, the ethnicity of participants, OR and upper and lower limit after correction. The Newcastle-Ottawa Scale was used to evaluate the quality of included studies (Table 2).

2.3. Statistical analysis

Meta-analysis was performed using STATA 12.0 software. HWE for each study was determined by the chi-square test to verify the representativeness of the study population. If \( P < .05 \), the genotypes of the control group were inconsistent with HWE. The relationship between rs735482 polymorphism and cancer risk was estimated by ORs and 95% CIs. Pooled ORs and 95% CIs for codominant (AC vs AA and CC vs AA), dominant (AC + CC vs AA), recessive (CC vs AC + AA), and the allelic (C vs A) genetic models were estimated. As for adjusted OR data, pooled ORs and 95% CIs for codominant (AB vs AA and BB vs AA), dominant (AB + BB vs AA), and recessive (BB vs AB + AA) genetic models were estimated. Z test was used to evaluate the significance of the pooled OR, and \( P < .05 \) was considered statistically significant. The results of the heterogeneity test were used to determine whether the fixed effect model or the random effect model. The heterogeneity test was measured by Q test and I² statistics. If the test result is \( I^2 \geq 50\% \) or \( P < .1 \), indicating the presence of heterogeneity, the random effect model is selected. Otherwise, the fixed-effects model is adopted. Begg’s funnel plots were conducted under all genetic models to assess the publication bias, and the asymmetric plots implied potential publication bias. The degree of asymmetry was measured using Egger’s test and \( P < .1 \) was considered a significant publication bias. The robustness was tested by leave-one-out sensitivity analyses.

3. Results

3.1. Study characteristics

Our meta-analysis included 10 case-control studies that met the inclusion criteria, including 2652 cancer cases and 3536 controls. Tables 1 and 2 show the characteristics and relevant data of the included studies.
3.2. Main analysis results

According to the results of the meta-analysis of 10 eligible studies, it was found that there was no correlation between rs735482 polymorphism and cancer risk of the general population in the codominant, dominant, recessive and allele model test (Fig. 2 and Table 3). Another adjusted OR data showed a significantly increased risk between rs735482 and several types of cancer susceptibility in the codominant model (BB vs AA) test (Fig. 3 and Table 4).

3.3. Subgroup analysis results

Stratified analysis of rs735482 polymorphism was done by ethnicity (Table 5). The data suggested that rs735482 was associated with an increased risk of cancers in the Chinese group (BB vs AA, OR = 1.391, 95% CI = 1.054–1.837, P = .020; AB + BB vs AA, OR = 1.253, 95% CI = 1.011–1.551, P = .039). However, rs735482 was associated with a decreased risk of cancers in Italian group (AB vs AA, OR = 0.600, 95% CI = 0.402–0.859, P = .012; AB + BB vs AA, OR = 0.620, 95% CI = 0.424–0.908, P = .014) (Fig. 4).

---

**Table 1**

Characteristics of the studies eligible for meta-analysis.

| Author         | Year | Country | Ethnicity | Case/control | AA  | AC  | CC  | AA  | AC  | CC  | HWE       | NOS score |
|----------------|------|---------|-----------|--------------|-----|-----|-----|-----|-----|-----|-----------|-----------|
| Jiaoyang Yin   | 2013 | China   | Asian     | 65/97        | 10  | 39  | 16  | 22  | 54  | 21  | 0.2635    | 7         |
| Jiaoyang Yin   | 2013 | China   | Asian     | 330/335      | 90  | 163 | 77  | 105 | 167 | 63  | 0.8126    | 7         |
| Tao Yu         | 2018 | China   | Asian     | 300/300      | 92  | 150 | 58  | 79  | 160 | 61  | 0.2219    | 7         |
| Nathan R. Jones| 2011 | America | Caucasian | 389/716      | 289 | 102 | 7   | 523 | 175 | 18  | 0.4652    | 9         |
| Huang Yu-liang | 2017 | China   | Asian     | 65/65        | 20  | 38  | 7   | 28  | 31  | 6   | 0.5334    | 7         |
| Qianye Zhang   | 2018 | China   | Asian     | 200/200      | 51  | 107 | 42  | 47  | 113 | 40  | 0.0632    | 7         |
| Nathan R. Jones| 2011 | America | Caucasian | 160/716      | 122 | 37  | 1   | 523 | 175 | 18  | 0.4652    | 9         |

HWE = Hardy–Weinberg equilibrium.

**Table 2**

Characteristics of the adjusted OR data for meta-analysis.

| Author         | Year | Country | Ethnicity | Case/control | (AB vs AA) OR | (BB vs AA) OR | (AB + BB vs AA) OR | (BB vs AA + AB) OR | NOS score |
|----------------|------|---------|-----------|--------------|---------------|--------------|--------------------|--------------------|-----------|
| Jiaoyang Yin   | 2016 | China   | Asian     | 330/335      | 1.28          | 0.89         | 1.85              | 1.66              | 1.06      | 2.62    | 1.38  | 0.98  | 1.96  | 1.42  | 0.97  | 2.09  | 7         |
| Fulvio Ricceri | 2009 | Italy   | Italian   | 324/283      | 0.6           | 0.4          | 0.89              | 0.82              | 0.25      | 2.67   | 0.62  | 0.42  | 0.9   | 0.94  | 0.29  | 3.03  | 8         |
| Jiaoyang Yin   | 2015 | China   | Asian     | 489/489      | 1.15          | 0.86         | 1.54              | 1.25              | 0.88      | 1.78   | 1.18  | 0.9   | 1.55  | 1.15  | 0.85  | 1.55  | 7         |

OR = odds ratio.
Table 3
The pooled ORs and 95% CIs for the association between ERCC1 rs735482A>C polymorphism and cancer susceptibility.

| Genetic model | Association | Heterogeneity | Publication bias |
|---------------|-------------|---------------|-----------------|
|               | OR (95% CI) | z             | P               | ?²  | P  | I² (%) | Begg's (P) | Egger's (P) |
| AC vs AA      | 1.014 (0.868–1.184) | 0.18          | .859            | 5.6 | .469 | 0       | .548       | .268       |
| CC vs AA      | 1.039 (0.810–1.325) | 0.28          | .779            | 7.3 | .294 | 17.8    | .548       | .57        |
| CC + AC vs AA | 1.012 (0.872–1.174) | 0.15          | .878            | 7.01 | .32   | 14.4    | .548       | .287       |
| CC vs AA + AC | 1.052 (0.850–1.300) | 0.46          | .643            | 4.67 | .587 | 0       | .23        | .151       |
| C vs A        | 1.019 (0.916–1.134) | 0.34          | .731            | 6.78 | .342 | 11.4    | .548       | .287       |

CI = confidence interval, OR = odds ratio.

Figure 3. The forest plot of the adjusted OR data for the relationship between ERCC1 rs735482 polymorphism and cancer susceptibility in the codominant model (BB vs AA).

Table 4
The pooled ORs and 95% CIs for the association between ERCC1 rs735482A>C polymorphism and cancer susceptibility of the adjusted OR data.

| Genetic model | Association | Heterogeneity | Publication bias |
|---------------|-------------|---------------|-----------------|
|               | OR (95% CI) | z             | P               | ?²  | P  | I² (%) | Begg's (P) | Egger's (P) |
| AB vs AA      | 0.972 (0.634–1.489) | 0.12          | .908            | 8.89 | .012 | 77.5    | 1           | .57        |
| BB vs AA      | 1.353 (1.033–1.774) | 2.19          | .028            | 1.67 | .435 | 0       | 1           | .708       |
| BB + AB vs AA | 1.014 (0.656–1.570) | 0.06          | .949            | 10.43 | .005 | 80.8    | 1           | .611       |
| BB vs AA + AB | 1.232 (0.977–1.554) | 1.77          | .077            | 0.93 | .627 | 0       | 1           | .835       |

CI = confidence interval, OR = odds ratio.

Table 5
Stratified analysis of ERCC1 rs735482A>C variant on cancer susceptibility.

| Subgroup   | Dominant (BB + AB vs AA) | Recessive (BB vs AA + AB) | Homozygous (BB vs AA) | Heterozygous (AB vs AA) |
|------------|--------------------------|---------------------------|-----------------------|------------------------|
|            | OR (95% CI)               | P-value                   | OR (95% CI)           | P-value                | OR (95% CI)         | P-value       |
| Total      | 3.104 (0.656–1.570)       | 80.8  | .949        | 1.232 (0.977–1.554)   | .077                  | 1.353 (1.033–1.774) | .028      | 0.972 (0.634–1.489) | 77.5  | .895    |
| Chinese    | 2.125 (1.011–1.551)       | 0.039 | 1.246 (0.983–1.578) | .068                  | 1.391 (1.054–1.837)   | .022                  | 1.199 (0.954–1.506) | 0.119 |
| Italian    | 1.62 (0.424–0.908)        | 0.014 | 0.940 (0.291–3.038) | 0.918                 | 0.820 (0.251–2.680)   | .743                  | 0.60 (0.402–0.895) | 0.012 |

P-value represents the association between ERCC1 rs735482 and cancer.

CI = confidence interval, OR = odds ratio.
3.3.1. Heterogeneity and publication bias. The heterogeneity of meta-analysis results is shown in Tables 2 and 3. The results showed that some studies had heterogeneity. The potential publication bias was estimated by Begg’s funnel plot and Egger’s test. As shown in Figure 5, the shape of funnel plots was symmetrical and no publication bias was observed.

3.3.2. Sensitivity analysis. A sensitivity analysis was performed to assess the impact of a particular publication on the overall assessment. The results of the relevant pooled ORs showed that there was no significant change when each study was neglected (Fig. 6). Thus, the final pooled results were both stable and reliable. But the relevant pooled ORs of the adjusted OR showed that significant change occurred when each study was neglected, one at a time, from the meta-analysis in dominant (BB + AB vs AA) and codominant (AB vs AA) genetic models (Fig. 7).

4. Discussion
A variety of studies have been conducted to determine whether rs735482 polymorphism affects the susceptibility of several types of cancer, and these findings have been controversial. In this meta-analysis, a total of 10 eligible case-control studies were included and their combined results were used to assess the relationship between rs735482 polymorphism and cancer susceptibility. Our meta-analysis showed that the rs735482 polymorphism had no significant effect on cancer risk. While the adjusted OR data showed a significantly increased risk between

![Figure 4](image-url)

**Figure 4.** The forest plot of the stratified analysis for the relationship between ERCC1 rs735482 polymorphism and cancer susceptibility in the dominant model (AB + BB vs AA).

![Figure 5](image-url)

**Figure 5.** The funnel plot for the test of publication bias in the recessive model (CC vs AC + AA).
Figure 6. Sensitivity analyses for studies between ERCC1 rs735482 polymorphism and cancer susceptibility in the allelic model (C vs A).

Figure 7. Sensitivity analyses of the adjusted OR data between ERCC1 rs735482 polymorphism and cancer susceptibility in the dominant model (AB + BB vs AA).
the rs735482 and susceptibility of several cancers (the codominant model BB vs AA, OR = 1.353, 95% CI: 1.033–1.774, P = .028), and the stratification analysis by ethnicity indicated the rs735482 was associated with an increased risk of cancers in Chinese group (BB vs AA, OR = 1.391, 95% CI: 1.054–1.837, P = .020; AB + BB vs AA, OR = 1.253, 95% CI = 1.011–1.551, P = .039) and a decreased risk of cancers in Italian group (AB vs AA, OR = 0.600, 95% CI = 0.402–0.859, P = .012; AB + BB vs AA, OR = 0.620, 95% CI = 0.424–0.908, P = .014).

In the stratified analysis of the adjusted OR data by ethnicity, we found that individuals carrying the variant C allele could increase the cancer susceptibility in Asians, but reduce cancer susceptibility of Italians, suggesting that racial differences might play an important role in genetic background variation.[24–26]

CD3EAP is a complementary nucleoprotein to ERCC1 and can participate in cell proliferation as part of the RNA polymerase I transcription complex.

Many studies have been published on the possible association between ERCC1 polymorphisms and cancers.[7,27–29] However, the most important studies that ERCC1 polymorphisms may be involved in are the functional studies relating to ERCC1 gene variant, repairability, and gene expression levels. All these results strongly support a possible role of ERCC1 in cancer risk. The ERCC1 rs735482 is located in the chromosomal region 19q1.3.3, and haplotypes of chromosome 19q13.2–3 have been associated with cancer risk in previous studies. ERCC1 rs735482 is involved in the identification and removing platinum-induced intra-strand adducts in DNA, and is resistant to platinum-based chemotherapy in many cancers, including non-small cell lung cancer, ovarian cancer, bone tumor, and colorectal cancer.[13,28–31]

There are several limitations in our meta-analysis. Firstly, there is heterogeneity between some studies. Heterogeneity can be attributed to differences in ethnicity, source of control, status, and type of cancer. Secondly, the language of the study is limited to English. Thirdly, although the combination of genetic factors and environmental exposure was taken into account in the adjusted OR, the number of studies and the sample size were small. Fourthly, different genotyping methods may lead to bias in the analysis. Finally, our meta-analysis was limited to Asian, Caucasian, Italian population and lack of other ethnicities.

To sum up, our meta-analysis showed that rs735482 polymorphism was not a risk factor for cancer, but the pooled adjusted OR showed that there was an association between the rs735482 polymorphism and susceptibility of several cancers, and the stratification analysis by ethnicity indicated the rs735482 was associated with an increased risk of cancer in Chinese while a decreased risk of cancer in Italian. To clarify the possible role of this mutation in cancer, further well-designed studies with larger samples number are required.

Acknowledgments
We greatly acknowledge Tao Yu,[32] Qianye Zhang,[21] and Jiaoyang Yin,[33,34] for they have provided the frequencies of rs735482 C/A polymorphism between the cases and controls in detail.

Author contributions
Shilin Xue, Wenyia Shen, and Jianming Cai wrote the main manuscript text and prepared all figures and tables. All authors reviewed the manuscript.

Data curation: Bingshuang Wang, Dan Zhao.
Funding acquisition: Xiaolin Zhang.
Methodology: Shan Zhang.

Software: Jinhai Jia.

Supervision: Xiujun Zhao.
Validation: Ning Ma, Wenjuan Wang.

Writing – original draft: Wenyia Shen, Xuehui Liu.
Writing – review & editing: Fengxue Yu, Jianning Cai, Shilin Xue.

References
[1] Iscovich J, Howe GR. Cancer incidence patterns (1972–91) among migrants from the Soviet Union to Israel. Cancer Causes Control 1998;9:29–36.
[2] Leitenstein GR. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment. Curr Opin Gastroenterol 2000;16:83–8.
[3] Yamazaki T, Hamano Y, Tashiro H, et al. CAST, a novel CD3 epsilon-binding protein transducing activation signal for interleukin-2 production in T cells. J Biol Chem 1999;274:18173–80.
[4] Veeramachaneni V, Makalowski W, Galdzicki M, Sood R, Makalowska I. Mammalian overlapping genes: the comparative perspective. Genome Res 2004;14:280–6.
[5] Yin J, Wang H, Vogel U, et al. Fine-mapping markers of lung cancer susceptibility in a subregion of chromosome 19q13.3 among Chinese. Oncotarget 2016;7:60929–39.
[6] Yin J, Wang H, Vogel U, Wang C, Hou W, Ma Y. Association and interaction of NFKB1 rs28362991 insertion/deletion ATTG polymorphism and PPP1R13L and CD3EAP related to lung cancer risk in a Chinese population. Tumour Biol 2016;37:5467–73.
[7] Vogel U, Larsos I, Jacobsen NR, et al. Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat Res 2004;546:63–74.
[8] Emlin JL, Scherer OD. The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nucleoside motif. EMBO J 2002;21:2045–53.
[9] Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J 1997;16:6559–73.
[10] Matsunaga T, Ma D, Park CH, Reardon JT, Sancar A. Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J Biol Chem 1995;270:20862–9.
[11] Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513–30.
[12] Iscovich J. Introduction to the Post-Human Genome Project era, a target for interactions between polygenic and/or multiphenotypical components in cancer control in South America. Cad Saude Publica 1998;14(Suppl 3):15–23.
[13] Li H, Ge X, Huang G, et al. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. Asian Pac J Cancer Prev 2012;13:3465–9.
[14] Schembri F, Sridhar S, Perdomo C, et al. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci USA 2009;106:2319–24.
[15] Pintarelli G, Cotroneo CE, Noci S, et al. Genetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci. Sci Rep 2017;7.
[16] Dai Q, Luo H, Li XP, Huang J, Zhou TJ, Yang Z. XRC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. Mutagenesis 2015;30:441–9.
[17] Jones NR, Spratt TE, Berg AS, Muscat JE, Lazarus P, Gallagher CJ. Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population. Cancer Epidemiol 2011;35:175–81.
[18] Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small-cell lung cancer. Carcinogenesis 2006;27:560–7.
[19] Ricceri F, Guarrera S, Sacerdote C, et al. ERCC1 haplotypes modify bladder cancer risk: a case–control study. DNA Repair (Amst) 2010;9:191–200.
[20] Chae YS, Kim JG, Kang BW, et al. PPP1R13L variant associated with prognosis for patients with rectal cancer. J Cancer Res Clin Oncol 2013;139:465–73.
[21] Zhang Q, Zheng X, Li X, et al. The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study. Cancer Med 2018;7:1264–74.

[22] Huang YL, Wu JR, Fang M, et al. The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e15090.

[23] Yin J, Vogel U, Guo L, Ma Y, Wang H. Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population. Cancer Genet Cytogenet 2006;164:66–70.

[24] Hirschhorn JN, Altshuler D. Once and again–issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002;87:4438–41.

[25] Hansen RD, Sorensen M, Tjonneland A, et al. A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer 2008;8:

[26] Schierup MH, Mailund T, Li H, et al. Haplotype frequencies in a sub-region of chromosome 19q13.3, related to risk and prognosis of cancer, differ dramatically between ethnic groups. BMC Med Genet 2009;10:

[27] Vogel U, Sorensen M, Hansen RD, et al. Gene-environment interactions between smoking and a haplotype of RAI ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett 2007;247:159–65.

[28] Kalikaki A, Voutsina A, Koutsopoulos A, et al. ERCC1 SNPs as potential predictive biomarkers in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Invest 2015;33:107–13.

[29] Qi B, Li Y, Wang N, Zhou R, Hu P, Kang S. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy]. Zhonghua Fu Chan Ke Za Zhi 2013;48:847–32.

[30] Hao T, Feng W, Zhang J, Sun Y, Wang G. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac J Cancer Prev 2012;13:3821–4.

[31] Khrunin A, Ivanova F, Moisseev A, et al. Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics 2012;13:171–8.

[32] Yu T, Xue P, Cui S, et al. Rs3212986 polymorphism, a possible biomarker to predict smoking-related lung cancer, alters DNA repair capacity via regulating ERCC1 expression. Cancer Med 2018;7:6317–30.

[33] Yin J, Guo L, Wang C, et al. Effects of PPP1R13L and CD3EAP variants on lung cancer susceptibility among nonsmoking Chinese women. Gene 2013;524:228–31.

[34] Yin J, Vogel U, Wang H, et al. HapMap-based study identifies risk sub-region on chromosome 19q13.3 in relation to lung cancer among Chinese. Cancer Epidemiol 2013;37:923–9.